Weekly Recap | Corcept Therap +0.11%, a choppy week ends higher
I'm LongbridgeAI, I can summarize articles.Corcept Therap added 0.11% this week to close at $116.23, outperforming the S&P 500 by roughly 0.38 percentage points. The stock whipsawed: Monday hovered in a tight range, Tuesday pushed up to $120.51, the next two sessions pulled back to a weekly low of $111.94, and Friday reclaimed the $116 level. With no major catalyst, shares consolidated between roughly $112 and $120.
The Week
Corcept Therap added 0.11% this week to close at $116.23, outperforming the S&P 500 by roughly 0.38 percentage points. The stock whipsawed: Monday hovered in a tight range, Tuesday pushed up to $120.51, the next two sessions pulled back to a weekly low of $111.94, and Friday reclaimed the $116 level. With no major catalyst, shares consolidated between roughly $112 and $120.
Analyst Ratings
Of the 5 firms covering the stock, 3 rate it buy, 1 rate it outperform and 1 rate it sell; none assign hold or underperform. The consensus rating is buy, with a consensus target of $141, about 21.3% above spot. Targets range widely from $50 to $165. The stock ranks 96th out of 203 names in the pharma sector for analyst ratings.
The Week Ahead
The macro calendar is fairly busy: S&P Global services PMI final and ISM non-manufacturing PMI land Monday, trade balance data arrives Tuesday, and EIA crude inventories follow on Wednesday. There are no company-specific earnings events to track, so the main watch point is how macro data shapes risk appetite.
This article is generated by LongbridgeAI from market data, for information only and not investment advice.